Stem cell factor is a novel independent prognostic biomarker for hepatocellular carcinoma after curative resection

Carcinogenesis

Volumn 35, Issue 10, 2014, Pages 2283-2290

  Wang, Xiuchao ^a   Ren, He ^a   Zhao, Tiansuo ^a   Chen, Jing ^a   Sun, Wei ^a   Sun, Yan ^a   Ma, Weidong ^a   Wang, Jian ^a   Gao, Chuntao ^a   Gao, Song ^a   Lang, Mingxiao ^a   Jia, Li ^b   Hao, Jihui ^a  

^a TIANJIN MEDICAL UNIVERSITY   (China)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CD34 ANTIGEN; STEM CELL FACTOR; TUMOR MARKER;

ADOLESCENT; AGE; ARTICLE; CANCER GRADING; CANCER PROGNOSIS; CANCER SURGERY; CAPILLARY DENSITY; CONTROLLED STUDY; FEMALE; GENDER; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; METASTASIS; MULTIVARIATE ANALYSIS; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECURRENCE FREE SURVIVAL; STATISTICAL ANALYSIS; CARCINOMA, HEPATOCELLULAR; CASE CONTROL STUDY; DISEASE FREE SURVIVAL; LIVER NEOPLASMS; METABOLISM; MORTALITY; PATHOLOGY; PROGNOSIS; TREATMENT OUTCOME;

ANTIGENS, CD34; CARCINOMA, HEPATOCELLULAR; CASE-CONTROL STUDIES; DISEASE-FREE SURVIVAL; HUMANS; KAPLAN-MEIER ESTIMATE; LIVER NEOPLASMS; PROGNOSIS; STEM CELL FACTOR; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84919822295     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgu162     Document Type: Article

References (48)

1. El-Serag, H.B. et al. (2007) Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology, 132, 2557-2576.
2. He, J. et al. (2005) Major causes of death among men and women in China. N. Engl. J. Med., 353, 1124-1134.
3. Jemal, A. et al. (2010) Cancer statistics, 2010. CA. Cancer J. Clin., 60, 277-300.
4. Mittal, S. et al. (2013) Epidemiology of hepatocellular carcinoma: consider the population. J Clin Gastroenterol, 47, S2-S6.
5. Floreani, A. et al. (2013) Risk factors associated with hepatocellular carcinoma in primary biliary cirrhosis. Hepatology, 58, 1520-1521.
6. El-Serag, H.B. (2011) Hepatocellular carcinoma. N. Engl. J. Med., 365, 1118-1127.
7. Autret, A. et al. (2010) Bcl-2 family proteins and mitochondrial fission/fusion dynamics. Cell. Mol. Life Sci., 67, 1599-1606.
8. Yan, T. et al. (2013) Prognosis of hepatocellular carcinoma: a study of 832 cases. Zhonghua Zhong Liu Za Zhi, 35, 54-58.
9. Cucchetti, A. et al. (2014) Estimation of lead-time bias and its impact on the outcome of surveillance for the early diagnosis of hepatocellular carcinoma. J. Hepatol., 61, 333-341.
10. Li, F. et al. (2013) Influencing elements and treatment strategies associated with the relapse of hepatocellular carcinoma after surgery. Hepatogastroenterology, 60, 1148-1155.
11. Matsui, J. et al. (2004) Stem cell factor/c-kit signaling promotes the survival, migration, and capillary tube formation of human umbilical vein endothelial cells. J. Biol. Chem., 279, 18600-18607.
12. Lennartsson, J. et al. (2012) Stem cell factor receptor/c-Kit: from basic science to clinical implications. Physiol. Rev., 92, 1619-1649.
13. Lennartsson, J. et al. (2006) The stem cell factor receptor/c-Kit as a drug target in cancer. Curr. Cancer Drug Targets, 6, 65-75.
14. Martinho, O. et al. (2008) KIT activation in uterine cervix adenosquamous carcinomas by KIT/SCF autocrine/paracrine stimulation loops. Gynecol. Oncol., 111, 350-355.
15. Krasagakis, K. et al. (2009) Co-expression of KIT receptor and its ligand stem cell factor in Merkel cell carcinoma. Dermatology, 218, 37-43.
16. Horstmann, M. et al. (2012) Evaluation of the KIT/stem cell factor axis in renal tumours. Anticancer Res., 32, 4339-4345.
17. Mansuroglu, T. et al. (2009) Expression of stem cell factor and its receptor c-Kit during the development of intrahepatic cholangiocarcinoma. Lab. Invest., 89, 562-574.
18. Aguilar, C. et al. (2014) Co-stimulation with stem cell factor and erythropoietin enhances migration of c-Kit expressing cervical cancer cells through the sustained activation of ERK1/2. Mol. Med. Rep., 9, 1895-1902.
19. Yang, X.R. et al. (2010) High expression levels of putative hepatic stem/progenitor cell biomarkers related to tumour angiogenesis and poor prognosis of hepatocellular carcinoma. Gut, 59, 953-962.
20. Kim, H. et al. (2013) Telomere length, TERT and shelterin complex proteins in hepatocellular carcinomas expressing "stemness"-related markers. J. Hepatol., 59, 746-752.
21. Mansuroglu, T. et al. (2009) Expression of stem cell factor receptor c-kit in human nontumoral and tumoral hepatic cells. Eur. J. Gastroenterol. Hepatol., 21, 1206-1211.
22. Casazza, A. et al. (2014) Tumor stroma: a complexity dictated by the hypoxic tumor microenvironment. Oncogene, 33, 1743-1754.
23. Dai, C.X. et al. (2009) Hypoxia-inducible factor-1 alpha, in association with inflammation, angiogenesis and MYC, is a critical prognostic factor in patients with HCC after surgery. BMC Cancer, 9, 418.
24. Mongiardi, M.P. (2012) Angiogenesis and hypoxia in glioblastoma: a focus on cancer stem cells. CNS Neurol. Disord. Drug Targets, 11, 878-883.
25. Sun, Y. et al. (2012) Molecular pathways: involving microenvironment damage responses in cancer therapy resistance. Clin. Cancer Res., 18, 4019-4025.
26. Keith, B. et al. (2007) Hypoxia-inducible factors, stem cells, and cancer. Cell, 129, 465-472.
27. Heddleston, J.M. et al. (2010) Hypoxia inducible factors in cancer stem cells. Br. J. Cancer, 102, 789-795.
28. Loboda, A. et al. (2012) HIF-1 versus HIF-2-is one more important than the other? Vascul. Pharmacol., 56, 245-251.
29. Matsubara, T. et al. (2013) TIE2-expressing monocytes as a diagnostic marker for hepatocellular carcinoma correlates with angiogenesis. Hepatology, 57, 1416-1425.
30. El-Assal, O.N. et al. (1998) Clinical significance of microvessel density and vascular endothelial growth factor expression in hepatocellular carcinoma and surrounding liver: possible involvement of vascular endothelial growth factor in the angiogenesis of cirrhotic liver. Hepatology, 27, 1554-1562.
31. Ker, C.G. et al. (1999) Role of angiogenesis in hepatitis and hepatocellular carcinoma. Hepatogastroenterology, 46, 646-650.
32. Gao, Q. et al. (2011) Tumor stroma reaction-related gene signature predicts clinical outcome in human hepatocellular carcinoma. Cancer Sci., 102, 1522-1531.
33. Poon, R.T. et al. (2002) Tumor microvessel density as a predictor of recurrence after resection of hepatocellular carcinoma: a prospective study. J. Clin. Oncol., 20, 1775-1785.
34. Elmasri, H. et al. (2012) Endothelial cell-fatty acid binding protein 4 promotes angiogenesis: role of stem cell factor/c-kit pathway. Angiogenesis, 15, 457-468.
35. Fujio, K. et al. (1994) Expression of stem cell factor and its receptor, c-kit, during liver regeneration from putative stem cells in adult rat. Lab. Invest., 70, 511-516.
36. Greaves, P. et al. (2013) Expression of FOXP3, CD68, and CD20 at diagnosis in the microenvironment of classical Hodgkin lymphoma is predictive of outcome. J. Clin. Oncol., 31, 256-262.
37. Jia, L. et al. (2014) Extracellular HMGB1 promotes differentiation of nurse-like cells in chronic lymphocytic leukemia. Blood, 123, 1709-1719.
38. Camp, R.L. et al. (2004) X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. Clin. Cancer Res., 10, 7252-7259.
39. Johnson, N.A. et al. (2012) Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J. Clin. Oncol., 30, 3452-3459.
40. Harrell, F.E. Jr et al. (1996) Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat. Med., 15, 361-387.
41. Song, P. et al. (2013) Biomarkers: evaluation of screening for and early diagnosis of hepatocellular carcinoma in Japan and China. Liver Cancer, 2, 31-39.
42. Mínguez, B. et al. (2011) Diagnostic and prognostic molecular markers in hepatocellular carcinoma. Dis. Markers, 31, 181-190.
43. Lee, S.C. et al. (2014) Prognostic biomarkers for prediction of recurrence of hepatocellular carcinoma: current status and future prospects. World J. Gastroenterol., 20, 3112-3124.
44. Williams, D.E. et al. (1990) Identification of a ligand for the c-kit protooncogene. Cell, 63, 167-174.
45. Zsebo, K.M. et al. (1990) Identification, purification, and biological characterization of hematopoietic stem cell factor from buffalo rat liver-conditioned medium. Cell, 63, 195-201.
46. Kim, H. et al. (2004) Primary liver carcinoma of intermediate (hepatocytecholangiocyte) phenotype. J. Hepatol., 40, 298-304.
47. He, G. et al. (2013) Identification of liver cancer progenitors whose malignant progression depends on autocrine IL-6 signaling. Cell, 155, 384-396.
48. Sidney, L.E. et al. (2014) Concise review: evidence for CD34 as a common marker for diverse progenitors. Stem Cells, 32, 1380-1389.